Can you provide an overview of retinoblastoma, including its epidemiology, clinical presentation, diagnostic workup, staging classifications, and management options?

Retinoblastoma: Overview

All children diagnosed with retinoblastoma—whether unilateral or bilateral—require germline RB1 genetic testing immediately, as approximately 45% have hereditary disease with lifelong cancer risks, and at least 15% of unilateral cases harbor germline mutations. 1

Introduction & Epidemiology

Retinoblastoma is the most common intraocular malignancy of childhood, affecting approximately 8,000 children worldwide annually (1:15,000-20,000 live births). 2 The disease exemplifies Knudson's two-hit hypothesis: biallelic inactivation of the RB1 tumor suppressor gene (chromosome 13q14.2) in retinal cone precursor cells drives malignant transformation. 1

Hereditary vs Non-Hereditary Disease

• Hereditary (45% of cases): Germline RB1 pathogenic variants with >90% penetrance for intraocular disease

  • Bilateral or multifocal unilateral disease = hereditary
  • 15% of unilateral unifocal cases are hereditary (often de novo mutations)
  • Autosomal dominant inheritance pattern 1

• Non-hereditary (55% of cases): Sporadic somatic mutations

  • Typically unilateral unifocal disease
  • ~10% driven by RB1 promoter methylation
  • ~1.4% driven by MYCN amplification (more aggressive, younger onset) 1

Critical pitfall: Tumor seeding can mimic multifocal disease, particularly with larger primary tumors and no family history. 1

Clinical Presentation

Leukocoria (white pupillary reflex) is the most common presenting sign, followed by strabismus. 3 Other presentations include:

• Proptosis (more common in Asian populations) 4
• Decreased vision
• Orbital inflammation
• Hyphema or vitreous hemorrhage
• Glaucoma

Predictors of hereditary disease in unilateral cases: Young age at diagnosis, macular tumor location, and multifocal presentation. 1

Diagnostic Workup

Initial Evaluation

Diagnosis is primarily clinical through dilated fundus examination under anesthesia, supplemented by ocular ultrasound. 4 Key diagnostic features:

• Ophthalmoscopy: White/cream-colored intraretinal mass with calcification, dilated feeder vessels
• Ultrasound: Hyperechoic mass with acoustic shadowing from calcification
• MRI orbit/brain: Evaluate extraocular extension, optic nerve involvement, and rule out trilateral retinoblastoma (pinealoblastoma)

Genetic Testing Strategy

Perform germline testing (blood, buccal, or saliva) on ALL children with retinoblastoma regardless of laterality. 1 Testing algorithm:

1. If bilateral disease: Proceed with surveillance regardless of test results (bilateral = hereditary)

2. If unilateral disease with negative germline test:

   • Consider mosaicism (3-5% of hereditary cases) 1
   • Ensure laboratory testing covers full RB1 gene and can detect low-level mosaicism
   • If enucleation performed, analyze tumor tissue for two RB1 hits to confirm sporadic disease

3. Tumor tissue analysis (if available from enucleation):

   • Identifies somatic mutations for liquid biopsy applications
   • Confirms germline variants
   • Detects MYCN amplification or promoter methylation 1

Emerging diagnostics: Aqueous humor cell-free DNA showing 6p gains correlates with aggressive phenotype and may guide treatment intensity. 1

Family Screening

All at-risk infants (siblings, offspring of affected individuals) require ophthalmologic examination within 24 hours of birth to maximize vision-sparing early detection. 1 Continue frequent screening until germline testing clarifies hereditary status—this applies to children of parents with unilateral OR bilateral disease. 1

Staging

American Joint Committee on Cancer (AJCC) 8th Edition TNMH System

The AJCC staging includes H (Heritable trait) classification to denote hereditary disease status, which fundamentally affects prognosis and surveillance. 1

Clinical staging (cT):

• cT1: Tumor confined to eye, <2/3 volume
• cT2: Tumor confined to eye, ≥2/3 volume
• cT3: Extraocular extension (includes optic nerve invasion beyond lamina cribrosa, choroidal invasion)
• cT4: Distant metastasis

International Classification of Retinoblastoma (ICRB)

Most widely used for intraocular disease treatment planning: 4

• Group A: Small tumors away from fovea/disc
• Group B: All remaining discrete tumors
• Group C: Focal subretinal/vitreous seeding
• Group D: Diffuse subretinal/vitreous seeding
• Group E: Extensive disease, no visual potential, features suggesting extraocular extension

Groups A-C have high globe salvage rates; Group D is challenging; Group E typically requires enucleation. 5

Management

Treatment Algorithm by Disease Extent

Intraocular Disease (Groups A-D)

Primary goal: Globe and vision salvage while ensuring survival. Treatment selection based on ICRB group:

Groups A-B (Small/Discrete Tumors):

• Focal therapy alone: laser photocoagulation, cryotherapy, or thermotherapy
• Excellent globe salvage rates (>90%) 5

Group C (Focal Seeding):

• Systemic chemoreduction (carboplatin, etoposide, vincristine) + focal consolidation
• Alternative: Intra-arterial chemotherapy (IAC) via ophthalmic artery
• Globe salvage: 70-80% 6

Group D (Diffuse Seeding):

• Combination approach: systemic or intra-arterial chemotherapy + intravitreal chemotherapy (melphalan)
• Intravitreal chemotherapy requires strict technique to prevent extraocular seeding (anterior chamber washout, needle tract cryotherapy) 5
• Globe salvage: 40-60% 6

Group E (Extensive Disease):

• Primary enucleation is standard with pathologic evaluation for high-risk features
• Consider neoadjuvant chemotherapy if orbital invasion suspected 5

High-Risk Pathologic Features Post-Enucleation

Massive choroidal invasion (>3mm or to sclera) and post-laminar optic nerve invasion predict metastasis and mandate adjuvant chemotherapy. 4 Microscopic residual disease at surgical margin requires aggressive treatment.

Extraocular/Metastatic Disease

• High-dose chemotherapy with autologous stem cell rescue
• External beam radiotherapy for CNS involvement
• Survival drops dramatically: <50% with extraocular extension 3

Radiation Therapy Considerations

External beam radiotherapy is highly effective but significantly increases subsequent malignant neoplasm (SMN) risk in hereditary cases—reserve for salvage situations only. 1 Alternatives include:

• Plaque brachytherapy (localized radiation, lower SMN risk)
• Proton beam therapy (reduced scatter to surrounding tissues)

Emerging Therapies

• Sustained-release chemotherapy devices (chemoplaques)
• Anterior chamber chemotherapy for anterior segment involvement
• Novel drug formulations and delivery methods under investigation 5

Surveillance Protocols

Intraocular Surveillance (Hereditary Cases)

Infants with germline RB1 mutations require examinations under anesthesia every 3-4 weeks until age 2 years, then gradually decreasing frequency until age 5-7 years when new tumor risk diminishes. 1 Prompt ophthalmologic examination within 24 hours of birth for at-risk infants. 1

Subsequent Malignant Neoplasm (SMN) Surveillance

Hereditary retinoblastoma survivors face lifelong elevated SMN risk, particularly sarcomas (bone and soft tissue), melanomas, and CNS tumors—risk amplified by radiation exposure. 1

Current evidence-based recommendations for asymptomatic adult survivors 7:

• Annual full-body skin examination for melanoma detection
• Prompt evaluation of any signs/symptoms (bone pain, masses, neurologic changes)
• No routine radiologic surveillance (MRI, CT) in asymptomatic patients—insufficient evidence of benefit and potential radiation harm 7

Critical counseling points:

• Lifetime SMN risk continues into adulthood
• Reproductive counseling regarding 50% transmission risk to offspring
• Avoid additional radiation exposure when possible (including diagnostic imaging) 7

Trilateral Retinoblastoma Surveillance

Brain MRI screening for pinealoblastoma in children <5 years with hereditary disease (risk highest in first 2-3 years of life). Frequency and duration remain debated but typically every 4-6 months until age 5.

Outcomes & Prognosis

Survival exceeds 95% in high-income countries with early diagnosis and specialized care, but remains <30-50% globally due to delayed presentation and limited resources. 2, 8

Factors associated with mortality 8:

• Advanced tumor stage (cT3 vs cT1: HR 4.65 × 10⁹)
• Age ≤4 years at diagnosis
• Female sex (HR 1.98)
• Lower-income country treatment setting

Globe salvage rates 8:

• cT1 disease: 70% at 3 years
• cT3 disease: 9% at 3 years
• Significant disparities between high-income (46%) and low-middle-income countries (13%)

The distinction between hereditary and non-hereditary disease fundamentally determines not only immediate treatment but lifelong surveillance strategies and family counseling needs. 1